Quartz·1 min read·medium
Eli Lilly's obesity pill showed it can ease sleep apnea in a late-stage trial
✦AI Summary
Eli Lilly's obesity medication, Foundayo, has demonstrated effectiveness in treating sleep apnea in a late-stage clinical trial. The company intends to seek FDA approval for this specific use by the end of 2026.
Why it matters
Highlights the expanding medical applications of GLP-1 receptor agonists, which could significantly impact the treatment landscape for obesity-related comorbidities.
Lilly plans to submit Foundayo to the FDA for moderate-to-severe sleep…
Also covering this story
One other newsroom covered this event. We read that version too.
healthbusiness
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in